Cerus Corp(CERS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 6:11 PM ET (Korea 10/30 07:11)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.03 | Insider Own | 5.38% | Shs Outstand | 201.5M | Perf Week | 5.63% |
| Market Cap | 0.49B | Forward P/E | - | EPS next Y | 72.22% | Insider Trans | -2.72% | Shs Float | 190.7M | Perf Month | 2.52% |
| Enterprise Value | 0.51B | PEG | - | EPS next Q | -0.01 | Inst Own | 75.64% | Short Float | 8.72% | Perf Quarter | 13.49% |
| Income | -0.01B | P/S | 2.22 | EPS this Y | 43.75% | Inst Trans | 0.65% | Short Ratio | 7.81 | Perf Half Y | 20.2% |
| Sales | 0.22B | P/B | 7.02 | EPS next 5Y | - | ROA | -3.24% | Short Interest | 16.63M | Perf YTD | 18.45% |
| Book/sh | 0.35 | P/C | 8.74 | EPS past 3/5Y | 30.31% 25.82% | ROE | -10.81% | 52W High | -29.68% ($3.47) | Perf Year | 68.28% |
| Cash/sh | 0.28 | P/FCF | - | Sales past 3/5Y | 8.35% 17.53% | ROIC | -5.98% | 52W Low | 76.81% ($1.38) | Perf 3Y | 92.13% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 65.57% | Gross Margin | 51.84% | Volatility(W/M) | 3.48% 3.84% | Perf 5Y | -63.03% |
| Dividend TTM | - | EV/Sales | 2.32 | Sales Y/Y TTM | 15.09% | Oper. Margin | -12.67% | ATR (14) | 0.09 | Perf 10Y | -50.31% |
| Dividend Ex-Date | - | Quick Ratio | 1.07 | EPS Q/Q | 50.67% | Profit Margin | -3.06% | RSI (14) | 55.02 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.83 | Sales Q/Q | 9.53% | SMA20 | 5.58% ($2.31) | Beta | 1.84 | Target Price | $5.12 |
| Payout | - | Debt/Eq | 1.1 | Earnings | 2026/11/2 | SMA50 | -1.55% ($2.48) | Rel Volume | 0.64 | Prev Close | $2.42 |
| Employees | 275 | LT Debt/Eq | 0.62 | EPS/Sales Surpr. | 24.81% 0.64% | SMA200 | -0.47% ($2.45) | Avg Volume(3M) | 2.13M | Price | $2.44 |
| IPO | 1997/1/31 | Option/Short | Yes/Yes | Trades | 3918 | Volume | 1,353,272 | Change | 0.83% |
🩸 Cerus is a medical company specializing in transfusion safety, with its core product being the INTERCEPT Blood System, which inactivates a broad range of pathogens—including viruses, bacteria, and parasites—that may be present in donated blood. With blood centers and hospitals as its primary customers, the company focuses on reducing the risk of infections transmitted through transfusions.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
Traded less than usual. That is 64% of its average volume.
Next earnings report: November 2
3 days to go.
CERS has a sound balance sheet but weak earning power
Of every $100 in sales, $12.67 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +43.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $222. Peers typically go for $345.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -63.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 75.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #59 of 142 in the industry
Based on market cap of $492M.
FAQ
What kind of company is CERS?
CERS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of CERS?
The market cap of CERS is approximately $492M, ranking 3,180 within its sector.
What is the 52-week high and low for CERS?
CERS has recorded a 52-week high of $3.47 and a low of $1.38.
